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The cysteine hydrolase, N-acylethanolamine acid amidase (NAAA)
is a promising target for analgesic and anti-inflammatory drugs.
Here, we describe the development of two unprecedented NAAA-
reactive activity-based probes as research tools for application in the
discovery of new inhibitors and for the in-depth characterization of
NAAA in its cellular environment.
The lysosomal cysteine hydrolase, N-acylethanolamine acid amidase
(NAAA), catalyses the hydrolytic degradation of palmitoylethanol-
amide (PEA),1,2 a bioactive lipid mediator that regulates pain and
inflammation by activating the ligand-operated transcription factor
PPAR-a (peroxisome proliferator-activated receptor-a).3,4 Catalytically
active NAAA is generated by auto-proteolysis, which occurs in acidic
cell compartments and releases the catalytic terminal nucleophile
cysteine (Cys131 in mice; Cys126 in humans).5–7 Several classes of
small-molecule NAAA inhibitors have been reported.8–12 These
include b-lactone, b-lactam8,9,11,12 and isothiocyanate derivatives,13
all of which act by reacting with the enzyme active-site thiol to form a
covalent bond. In addition, a class of benzothiazole-piperazine
derivatives has been recently disclosed, which inhibits NAAA via a
non-covalent mechanism.10 Given the growing interest in NAAA as a
potential drug target,4,10 it is important to develop tools that facilitate
screening of NAAA inhibitors and that allow monitoring of NAAA
activity in live cells. We have recently described a NAAA activity-based
probe (ABP) (CC-ABP 1, Fig. 1a),14,15 which was designed based
on the systemically active b-lactam inhibitor, ARN726 (2)
(4-cyclohexylbutyl-N-[8]-carbamate) (Fig. 1a). Compound 1 con-
tains a terminal alkyne tag that allows for copper-catalyzed
azide–alkyne [2+3] ‘click’ cycloaddition with an azide bearing a
reporter tag.16–18 In activity-based protein profiling (ABPP)
experiments, CC-ABP 1 has been used to capture the catalytically
active form of NAAA from cell cultures and live animals and to
detect increased NAAA activation in inflamed rat tissues.15,19
Moreover, CC-ABP 1 has been utilized in competitive ABPP
experiments, which proved the engagement of NAAA by the
non-covalent benzothiazole–piperazine NAAA inhibitors.10
Despite the interesting results achieved, the use of CC-ABP 1
remains limited by the two-step labelling experimental
approach. In this context, the target enzyme detection is only
possible after the ‘‘click’’ reaction of the azide-tag molecule with
the reactive alkyne group of the probe, resulting in unhandy
and time-consuming sample preparation. Moreover, the use of
copper(I) salts for the fluorophore installation, renders CC-ABP
1 not compatible with applications in living cells.
Fig. 1 Structure of (a) serine-derived b-lactam CC-ABP 1 and its parent
molecule ARN726, 2; (b) novel N-O-substituted b-lactam BODIPY-ABP 3
and norbornene derived-ABP 4; (c) covalent b-lactam (5, 6) and non-
covalent (7) NAAA inhibitors used in the present study.
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Here, we disclose two new chemical tools for the study of
NAAA (Fig. 1b): BODIPY-ABP 3, which permits the detection of
the enzyme in complex proteome samples without the two-step
labelling procedure that is required for compound 1, and
norbonene-ABP 4, which can be used to study catalytically
active NAAA in intact cells by means of an inverse-electron-
demand Diels-Alder (IEDDA) reaction between 1,2,4,5-tetrazine
and a norbornene moiety, a bioorthogonal ligation reaction
originally developed by Devaraj et al.20 for live-cell imaging of
cell surface receptors.
We used the recently published N-O-substituted threonine-
b-lactam scaffold11 (5, 6, Fig. 1c) as a chemical template for the
synthesis of the new probes (see ESI† for detailed synthetic
procedures). Both compounds were prepared starting from the
N-O-methylsulfonylphenyl b-lactam N-Boc carbamate (Scheme 1 and
Scheme S1, ESI†) which was first converted into the corresponding
tosylate salt. Then, a subsequent carbamoylation reaction allowed
the functionalization of the exocyclic amino group with the desired
bioorthogonal groups. Azide-b-lactam 921 (Scheme 1) was reacted
with BODIPY alkyne 1022 in a copper(I)-catalyzed [2+3] cycloaddition
reaction to yield compound 3. The norbornene-derived b-lactam 4
(Scheme 1) was obtained from the corresponding chloroformate
(S7, Scheme S2, ESI†), previously synthesized from norbornene
alcohol S6 (Scheme S2, ESI†). We evaluated the inhibitory activity
of 3 and 4 for human (h) NAAA as previously described.11 Unlike
formerly observed for other b-lactams,8,9 the insertion of a
bulky BODIPY reporter group or a heteroatom in the carbamic
acid ester side chain preserved a significant inhibitory activity
for both compounds (3, IC50 = 0.35 mM; 4, IC50 = 0.06 mM).
Next, we defined appropriate experimental conditions for
ABPP labelling of NAAA by the two probes (Fig. 2). Lysosome-
enriched extracts from hNAAA-overexpressing HEK293 cells
were incubated with both ABPs 3 and 4, and the reactions were
analysed by in-gel fluorescent electrophoresis. BODIPY-ABP 3
labelled NAAA in a concentration-dependent manner (Fig. 2a).
Moreover, as shown in Fig. 2a, the correlation between concen-
tration of compound 3 and signal intensity was linear between
0.1 and 2.5 mM. The mid-point concentration of 1 mM was
selected for subsequent experiments.
Norbonene-ABP 4 was tested in the presence of various
concentrations of BODIPY GREEN-tetrazine 1123 (Fig. 2b) in a
two-step, IEDDA-mediated ABPP protocol. As shown in Fig. 2c,
the best results were achieved when BODIPY GREEN-tetrazine
11 was used at 10 mM for all tested concentrations of 4 (1, 5, or
10 mM).
To evaluate the effectiveness of the new BODIPY-ABP 3 in the
screening for NAAA inhibitors by competitive ABPP, lysosome-
enriched extracts from hNAAA-overexpressing HEK293 cells
were incubated with inhibitors of different potencies (Fig. 3):
the newly synthesized norbornene-ABP 4 (IC50 = 0.06 mM), the
serine-derived b-lactam NAAA inhibitor 28 (IC50 = 0.073 mM;
Fig. 1a) and its recently identified N-O-substituted analogues 5
and 611 (5, IC50 = 0.006 mM; 6, IC50 = 0.4 mM; Fig. 1c).
Additionally, to test inhibitors with different mechanisms of
action, we also evaluated the non-covalent NAAA inhibitor 710
(IC50 = 0.230 mM; Fig. 1c). BODIPY-ABP 3 was next added to the
inhibitor-incubated samples. As shown in Fig. 3a, when cell
extracts were pre-incubated with 2, 4, 5 or 7, NAAA labelling
with 3 was almost completely abolished, indicating close to full
Scheme 1 Reagents and conditions: (a) p-toluenesulfonic acid, TFA,
room temperature, 15 min; (b) S7, DIPEA, dry DCM, room temperature,
15 h; (c) 5-azidopentyl chloroformate, DIPEA, dry DCM, room temperature,
15 h; (d) BODIPY alkyne 10, CuSO45H2O, sodium ascorbate, DMF, room
temperature, 15 h.
Fig. 2 (a) Left, in-gel fluorescence scanning (488 nm) of a lysosomal
extract from HEK293 cells overexpressing hNAAA (15 mg), incubated for
30 min at 37 1C with various concentrations of 3. The titration curve on the
right shows that the response is linear for a concentration up to 2.5 mM.
(b) Structure of the BODIPY GREEN tetrazine 11 used in the study.23
(c) In vitro ABPP on lysosome-enriched extracts from hNAAA-overexpressing
HEK293 cells incubated with 4 (0–10 mM, 30 min at 37 1C) followed by addition
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inhibition at the tested concentration. Compound 6 did not
fully inhibit NAAA activity at the used concentration (10 mM),
but did so when a higher concentration was used (Fig. 3b and
c). The results indicate that probe 3 is a fast and effective tool
for the screening of both covalent and non-covalent NAAA
inhibitors.
In the next experiments, we examined whether norbornene-
ABP 4 was able to cross the cell membrane and therefore detect
active NAAA in intact cells (Fig. 4a). To this end, we incubated
intact HEK-293 cells overexpressing hNAAA with 4 (1 mM final
concentration) for one hour. Next, cells were lysed and the
protein extract was incubated with the BODIPY GREEN-tetrazine
11 (ESI†). As shown in Fig. 4a, a clear band corresponding to the
catalytically active subunit of NAAA was detected, confirming that
4 was able to reach its intracellular target. The same experiment,
performed on wild-type HEK-293 cells acted as a negative control
(Fig. 4a). A Western blot experiment with a NAAA-specific antibody
was performed to check NAAA expression in the analysed samples
(Fig. 4a, bottom). Cells, which were incubated with norbornene-
ABP 4, were further analysed by confocal microscopy. For this
purpose, probe-labelled cells were fixed and immunostained
using a NAAA antibody. The cells were then incubated with
BODIPY GREEN-tetrazine 11 (ESI†). As shown in Fig. 4b, intra-
cellular norbornene-labelled enzyme (panel b2, in green) was
readily detected with an excellent signal intensity and low back-
ground noise. In red (panel b3), the signal corresponding to the
anti-NAAA antibody is shown. In the merged image (panel b4), red
and green signals did not completely co-localize (yellow), and
compound 4 only labels a fraction of the total NAAA present in
cells (red signal). The red signal corresponds in all likelihood to
the full-length inactive enzyme, while the yellow signal represents
the enzyme activated by autocatalytic cleavage in the cell acidic
compartments. This result suggests that only part of the total
enzyme pool is activated in the analysed cells. Wild-type HEK-293
cells were also examined, proving the absence of unspecific
staining for both the probe and the antibody (Fig. S1, ESI†). The
experimental outcome highlights a novel promising feature of the
probe: unlike available NAAA-specific antibodies, which react with
both the inactive full-length enzyme and the active subunit, ABP 4
can clearly detect the active form of NAAA and distinguish it from
the inactive enzyme in an imaging experiment.
In conclusion, the present results identify two novel NAAA-
reactive probes, 3 and 4, which are based on the structure of the
potent N-O-substituted threonine b-lactams, 5 and 6. BODIPY-
ABP 3 may be used as a tool to define novel classes of NAAA
inhibitors. The norbornene-ABP 4 may be utilized instead to
label NAAA in situ, with the advantage of detecting selectively
the active subunit of the enzyme in its natural cellular environ-
ment. In addition, the copper(I)-free experimental conditions
Fig. 3 (a) Competitive ABPP using lysosomal extracts of hNAAA-
overexpressing HEK293 cells (15 mg of protein) pre-incubated with DMSO
or the indicated inhibitors (10 mM, 1 h at 37 1C) before probe 3 addition
(1 mM, 30 min at 37 1C). In-gel fluorescence scanning (488 nm) (top) and
Coomassie Blue staining (loading control, bottom). (b) In-gel fluorescence
scanning of lysosomal extract (15 mg) from hNAAA-overexpressing HEK293
cells pre-incubated with various concentrations of 6 for 1 h at 37 1C before
incubation with ABP 3 (1 mM) for 30 min at 37 1C. Reported images are
representative of three independent experiments. (c) Dose response curve
for 6 obtained by intensity determination of bands reported in panel b.
Signals obtained in the absence of inhibitors represent 100% of enzyme
activity. The means of three independent experiments and standard
deviations are plotted.
Fig. 4 (a) Experiment on intact overexpressing hNAAA HEK293 cells,
incubated for 1 h with 4 (1 mM) or vehicle (0.5% DMSO). The total lysates
of DMSO- and probe-treated cells were next incubated with 10 mM
tetrazine-BODIPY. Samples (10 mg) were analysed by in-gel fluorescence
scanning (top) or Western blot using an anti-NAAA antibody (bottom).
(b) Imaging of probe treated cells. Fluorescence microscopy analysis of
hNAAA-overexpressing HEK293, which were pre-treated with probe 4
(1 mM). Cells were fixed and incubated with an anti-NAAA antibody and an
Alexa Fluor 647 secondary reagent (in red) followed by 5 mM of BODIPY
GREEN-tetrazine 11 (in green). Nuclei were marked with DAPI (blue). Scale
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employed in the IEDDA-mediated ABPP protocol, make 4 a
potentially useful tool to investigate cellular and subcellular
localization of NAAA in living cells and tissues.
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